AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study

Inclusion Criteria: * Age \>= 18 \<85 years * Patient is currently treated with an ACEI * Patient must have acute angioedema attack caused by an ACEI * Treatment should be administrated within 10 hrs after onset by an ACEI * Patient with angioedema of head and /or neck (face, lips, cheeks, tongue, soft palate/uvula, pharynx and larynx) * At least one moderate to severe severe angioedema symptom as assessed by the investigator, requiring a medical intervention * Signed written Informed Consent Form Exclusion Criteria: * Diagnosis of angioedema that was not caused by ACEI: e.g. hereditary angioedema (C1-INH deficiency), allergy, anaphylaxis, insect bite, trauma, infection, abscess, tumor, post-radiation or post-operative or processes related to salivary glands and others where it is unlikely that the ACEI is causing the angioedema * Participation in a clinical trial of another investigational medicinal product (IMP) within 30 days * Patients with acute urticaria * Patients with a medical history of any angioedema before taking an ACEI * Patients with an acute rash or hives in the face or somewhere else * Unstable angina or acute myocardial infarction * Acute heart failure * Serious concomitant illnesses that the physician considers to be a contraindication for participation in the trial * Pregnancy and/or breast-feeding * Mental condition rendering the patients, in the opinion of the investigator, unable to understand the nature, scope and possible consequences of the study; * Unlikely to comply with the protocol, e.g., uncooperative attitude, inability to return for the follow-up visit, or unlikely to complete the study for any reason.